Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Novartis Ag (NVSEF) Return on Sales (2016 - 2025)

Historic Return on Sales for Novartis Ag (NVSEF) over the last 17 years, with Q4 2025 value amounting to 3.89%.

  • Novartis Ag's Return on Sales rose 36400.0% to 3.89% in Q4 2025 from the same period last year, while for Dec 2025 it was 4.98%, marking a year-over-year increase of 47100.0%. This contributed to the annual value of 0.26% for FY2025, which is 200.0% up from last year.
  • Latest data reveals that Novartis Ag reported Return on Sales of 3.89% as of Q4 2025, which was up 36400.0% from 5.75% recorded in Q3 2025.
  • In the past 5 years, Novartis Ag's Return on Sales registered a high of 6.71% during Q1 2025, and its lowest value of 0.0% during Q2 2023.
  • In the last 5 years, Novartis Ag's Return on Sales had a median value of 0.26% in 2024 and averaged 1.23%.
  • Its Return on Sales has fluctuated over the past 5 years, first plummeted by -12700bps in 2022, then soared by 64400bps in 2025.
  • Novartis Ag's Return on Sales (Quarter) stood at 1.28% in 2021, then tumbled by -99bps to 0.01% in 2022, then surged by 3482bps to 0.51% in 2023, then tumbled by -51bps to 0.25% in 2024, then soared by 1456bps to 3.89% in 2025.
  • Its Return on Sales was 3.89% in Q4 2025, compared to 5.75% in Q3 2025 and 4.23% in Q2 2025.